Q2 2025 Earnings Summary
Metric | YoY Change | Reason |
---|---|---|
Total Revenue | -4.3% | Total Revenue declined from $10.4 million to $9.953 million due to a noticeable drop in OUS sales, particularly the steep contraction in the UK segment, which more than offset the stable performance in domestic markets. |
Domestic Revenue | Essentially unchanged | Domestic Revenue remained steady at approximately $5.865 million compared to $5.831 million the previous year, showing resilience in core operations even though previous periods were impacted by factors such as supply chain disruptions and OEM sales declines. |
Outside U.S. Revenue | -10.5% | OUS Revenue dropped from $4.569 million to $4.088 million, driven by ongoing global challenges, including weaker OEM sales, non-recurrence of sporadic large orders seen in earlier periods, and adverse foreign currency effects that have gradually weighed on international performance. |
UK Revenue | -69% | UK Revenue contracted sharply from $3.042 million to $0.947 million, which may reflect significant market-specific challenges such as local litigation transfers and deteriorating customer demand—issues that have been noted in past periods and have now deepened. |
Other OUS Revenue | N/A (emerging segment) | This segment registered $1.492 million in Q2 2025 with no prior comparable data, indicating an emerging contribution that contrasts with declines in established OUS categories, possibly paving the way for future revenue diversification despite current challenges. |
Research analysts covering UTAH MEDICAL PRODUCTS.